Verve Therapeutics Stock Performance
| VERV Stock | USD 6.23 0.07 1.11% |
On a scale of 0 to 100, Verve Therapeutics holds a performance score of 5. The entity has a beta of 0.63, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Verve Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Verve Therapeutics is expected to be smaller as well. Please check Verve Therapeutics' sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to make a quick decision on whether Verve Therapeutics' existing price patterns will revert.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Verve Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, Verve Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (8.35) | Five Day Return (7.90) | Year To Date Return (59.21) | Ten Year Return (82.11) | All Time Return (82.11) |
1 | Verve Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi Korsinsky Before October 28, 2024 to Discuss Your Rights VERV | 10/16/2024 |
2 | Levi Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics Lawsuit - VERV | 10/23/2024 |
3 | Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results | 11/05/2024 |
4 | Verve Therapeutics Third Quarter 2024 Earnings Beats Expectations | 11/06/2024 |
5 | Verve Therapeutics Trading Up 10.1 percent After Strong Earnings | 11/08/2024 |
6 | Insider Trading | 11/15/2024 |
7 | Disposition of 49569 shares by Gv 2017 Gp, L.l.c. of Verve Therapeutics subject to Rule 16b-3 | 11/22/2024 |
8 | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635 | 11/29/2024 |
9 | Disposition of 555 shares by Allison Dorval of Verve Therapeutics at 5.64 subject to Rule 16b-3 | 12/02/2024 |
10 | Verve Therapeutics Cutting-Edge Science But Highly Risky Stock - Seeking Alpha | 12/03/2024 |
11 | Acquisition by Kathiresan Sekar of 30000 shares of Verve Therapeutics subject to Rule 16b-3 | 12/04/2024 |
12 | Jacobs Levy Equity Management Inc. Increases Holdings in Verve Therapeutics, Inc. - MarketBeat | 12/06/2024 |
13 | Verve Therapeutics, Inc. Class Action The Gross Law Firm Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline... | 12/10/2024 |
| Begin Period Cash Flow | 120.2 M |
Verve |
Verve Therapeutics Relative Risk vs. Return Landscape
If you would invest 542.00 in Verve Therapeutics on September 15, 2024 and sell it today you would earn a total of 81.00 from holding Verve Therapeutics or generate 14.94% return on investment over 90 days. Verve Therapeutics is currently generating 0.3778% in daily expected returns and assumes 5.8582% risk (volatility on return distribution) over the 90 days horizon. In different words, 52% of stocks are less volatile than Verve, and 93% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Verve Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Verve Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Verve Therapeutics, and traders can use it to determine the average amount a Verve Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0645
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | VERV | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.86 actual daily | 52 52% of assets are less volatile |
Expected Return
| 0.38 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 5 95% of assets perform better |
Based on monthly moving average Verve Therapeutics is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Verve Therapeutics by adding it to a well-diversified portfolio.
Verve Therapeutics Fundamentals Growth
Verve Stock prices reflect investors' perceptions of the future prospects and financial health of Verve Therapeutics, and Verve Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Verve Stock performance.
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (8.29) % | ||||
| Current Valuation | 64.72 M | ||||
| Shares Outstanding | 84.66 M | ||||
| Price To Earning | 5.45 X | ||||
| Price To Book | 1.04 X | ||||
| Price To Sales | 21.86 X | ||||
| Revenue | 11.76 M | ||||
| Gross Profit | (128.15 M) | ||||
| EBITDA | (217.67 M) | ||||
| Net Income | (200.07 M) | ||||
| Cash And Equivalents | 293.56 M | ||||
| Cash Per Share | 4.90 X | ||||
| Total Debt | 74.91 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 11.55 X | ||||
| Book Value Per Share | 6.01 X | ||||
| Cash Flow From Operations | (149.55 M) | ||||
| Earnings Per Share | (2.46) X | ||||
| Market Capitalization | 533.38 M | ||||
| Total Asset | 752.69 M | ||||
| Retained Earnings | (544.3 M) | ||||
| Working Capital | 600.94 M | ||||
About Verve Therapeutics Performance
Evaluating Verve Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Verve Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Verve Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.27) | (0.28) | |
| Return On Capital Employed | (0.31) | (0.33) | |
| Return On Assets | (0.27) | (0.28) | |
| Return On Equity | (0.33) | (0.32) |
Things to note about Verve Therapeutics performance evaluation
Checking the ongoing alerts about Verve Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Verve Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Verve Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 11.76 M. Net Loss for the year was (200.07 M) with loss before overhead, payroll, taxes, and interest of (128.15 M). | |
| Verve Therapeutics currently holds about 293.56 M in cash with (149.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.9. | |
| Over 98.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: Verve Therapeutics, Inc. Class Action The Gross Law Firm Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - Longview News-Journal |
- Analyzing Verve Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Verve Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Verve Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Verve Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Verve Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Verve Therapeutics' stock. These opinions can provide insight into Verve Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Verve Stock Analysis
When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.